You have   6 free profiles   left this month    Start Your Free Trial ➤
Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there? View on RelSci Pro ➤

Michel Bouvier

Chairman, Scientific Advisory Board at Domain Therapeutics SA
Overview
Relationships
In The News
Paths
Boards & Committees

Michel Bouvier

Chairman, Scientific Advisory Board at Domain Therapeutics SA

Overview

Board Seats
2
Number of Relationships
This person is connected to 44 people.

Relationships See Details


Founder at Applied Genetic Technologies Corp.

Professor Emeritus, Biochemistry at Brandeis University

Professor, Department of Biochemistry & Molecular Biophysics at Washington University in St.Louis - School of Medicine

Chief Executive Officer, Director & Chief Scientific Officer at Domain Therapeutics SA

Chief Executive Officer at Amicus Therapeutics, Inc.

Founder at Domain Therapeutics SA

Founder at Domain Therapeutics SA

Founder at Domain Therapeutics SA

Vice President-Research & Development at Vertex Pharmaceuticals

Partner at Seventure Partners SA
See 34 more listings with RelSci Professional.

In The News See More

PR Newswire
June 15, 2015
peHUB
April 8, 2015
PR Newswire
November 10, 2014
FierceBiotech
September 26, 2014

Paths to Michel Bouvier

Michel Bouvier
You
Connections via Relationship Science
Michel Bouvier
Sync your contacts to see how you can connect with Michel Bouvier.

Boards & Committees

Corporate Boards ▾
Chairman, Scientific Advisory Board
2014 - Current
Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm’s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Israël, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in October 2001 and is headquartered in Illkirch-Graffenstaden, France.
Member, Scientific Advisory Board
Tenure Unconfirmed
Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Other Affiliations

Michel Bouvier is affiliated with Domain Therapeutics SA, Amicus Therapeutics, Inc..

You've reached your 7 free profiles limit this month.

Upgrade to RelSci Pro today to enjoy unlimited profile views and much more!

Start My Free Trial
Still not convinced? Check out our full listing of features here.